Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

AP301 phase 3 trial highlights Alebund’s potential to differentiate in HP space, says GlobalData

Alebund Pharmaceuticals announced positive topline phase III results highlighting that the use of AP301 demonstrated a statistically significant and clinically meaningful improvement in serum phosphorus control in dialysis patients with hyperphosphatemia (HP). If approved, AP301 could potentially address two unmet needs in HP management: poor patient adherence and inadequate phosphorus control, says GlobalData, a leading […]
Read more

FDA approves 127 innovator and biosimilar drugs in 2024, marks shift in pharmaceutical approval landscape, says GlobalData

The US Food and Drug Administration (FDA) announced the approval of 127 innovator and biosimilar drugs in 2024, a notable decrease from the 149 approvals recorded in 2023. Despite the decline in overall approvals, the year saw a remarkable surge in innovative drug approvals, particularly from small pharmaceutical companies, many of which secured their first […]
Read more

Eli Lilly’s orforglipron and other key catalysts set to reshape drug landscape in Q3 2025, says GlobalData

Eli Lilly and Co’s orforglipron is emerging as a promising oral glucagon-like peptide (GLP)-1 therapy, with upcoming clinical milestones in obesity and diabetes set to shape its market trajectory. As a wave of key catalysts—including FDA decisions and late-stage trial results—approaches in Q3 2025, the pharmaceutical landscape is poised for shifts driven by innovation, competitive […]
Read more

Big Pharma prepare for next patent cliff as blockbuster drugs revenue losses loom, says GlobalData

The pharmaceutical industry is bracing for one of its most financially significant patent cliffs in over a decade, with multiple blockbuster drugs set to lose exclusivity by 2030. As biosimilars and generics flood the market, pricing pressures will intensify—particularly in oncology—challenging pharma companies to rethink revenue strategies, pipeline investments, and lifecycle management to safeguard long-term […]
Read more

Lineage Cell Therapeutics’ OpRegen holds potential to become new treatment option for GA, says GlobalData

Lineage Cell Therapeutics’ OpRegen (RG6501) is gaining attention as a promising one-time allogenic cell therapy for geographic atrophy (GA), following encouraging results from its Phase I/IIa trial. With limited treatment options currently available, OpRegen’s ability to improve and stabilize vision positions it as a potential breakthrough in addressing a critical unmet need in GA management, […]
Read more

Challenges mount for big pharma in China as vaccine sales plummet, says GlobalData

Multinational pharmaceutical companies (MNCs) are facing significant challenges in China’s vaccine market, as regulatory scrutiny, domestic competition, and changing consumer behaviors disrupt a once-thriving sector. Major players like Merck & Co. and GSK are re-evaluating their strategies in light of these developments, says GlobalData, a leading data and analytics company. GlobalData’s Q2 2025 Emerging Market […]
Read more

High costs and limited access threaten progress in HIV treatment despite new drug advances, says GlobalData

Despite major strides in antiretroviral therapy (ART), the human immunodeficiency virus (HIV) market still faces serious challenges that threaten long-term control of the disease. The most pressing issue is the lack of affordable access to newer therapies, which—despite offering better adherence and fewer side effects—remain out of reach for many patients due to high costs […]
Read more

Vutrisiran to change ATTR-CM treatment paradigm in Europe, says GlobalData

Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol in the bloodstream. It can cause ATTR-cardiomyopathy (ATTR-CM) or ATTR-polyneuropathy (ATTR-PN). As effective treatments for ATTR-CM are still limited, Alnylam Pharmaceuticals’ drug vutrisiran is expected to change ATTR-CM treatment paradigm upon market launch in Europe, […]
Read more

Nontuberculous mycobacteria market to reach $4.6 billion in 7MM in 2033, forecasts GlobalData

The nontuberculous mycobacteria (NTM) market across the seven major markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 8.8% from $2.0 billion in 2023 to $4.6 billion in 2033, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, “Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast”, reveals that […]
Read more

Diagnosed prevalent cases of multiple sclerosis to increase by 0.19% AGR in 7MM during 2024-34, forecasts GlobalData

The diagnosed prevalent cases of multiple sclerosis (MS) in the seven major markets (7MM*) are projected to increase from 1.61 million in 2024 to 1.64 million in 2034 at an annual growth rate (AGR) of negative 0.19%, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Multiple Sclerosis Epidemiology Analysis and Forecast to […]
Read more

Diagnosed prevalent cases of pulmonary arterial hypertension to decline by 0.08% AGR in 7MM during 2024-34, forecasts GlobalData

The diagnosed prevalent cases of pulmonary arterial hypertension (PAH) in the seven major markets (*7MM) are projected to decrease from 76,645 in 2024 to 76,035 in 2034 at an annual growth rate (AGR) of negative 0.08%, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Pulmonary Arterial Hypertension (PAH) – Epidemiology Analysis and […]
Read more
1 … 6 7 8 9 10 … 108